Tissue-Based Revenue was MDxHealth’s largest revenue line in fiscal 2025, bringing in $81.49M of $107.88M (76%).
| Products and services [axis] | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Tissue-Based Revenue | $31.15M | $55.72M | $72.33M | $81.49M |
| Liquid-Based Revenue | $5.81M | $14.25M | $17.58M | $26.06M |
| Royalties & Other Revenues | $89.00K | $228.00K | $139.00K | $326.00K |
| Total | $37.05M | $70.19M | $90.05M | $107.88M |
MDxHealth brought in $107.88M from its three revenue lines in fiscal 2025, the year ended December 31, 2025. That was up 19.8% from $90.05M in fiscal 2024. Tissue-Based Revenue was the largest at $81.49M (75.5%), ahead of Liquid-Based Revenue at $26.06M (24.2%) and Royalties & Other Revenues at $326.00K (0.3%).
Compared with fiscal 2024, Liquid-Based Revenue grew 48.2% to $26.06M and Tissue-Based Revenue grew 12.7% to $81.49M. From fiscal 2022 to 2025, combined revenue from these revenue lines grew from $37.05M to $107.88M, a compound annual growth rate of 42.8%. Tissue-Based Revenue's share of the total fell from 84.1% to 75.5%.
MDxHealth (MDXH) reports its revenue by products and services [axis]. In fiscal 2025, Tissue-Based Revenue was its largest revenue line, bringing in $81.49M (75.5% of the total), followed by Liquid-Based Revenue at $26.06M (24.2%).
Tissue-Based Revenue was MDxHealth's largest revenue line in fiscal 2025, bringing in $81.49M, or 75.5% of the $107.88M total across its three revenue lines.
Liquid-Based Revenue grew faster than Tissue-Based Revenue in fiscal 2025, up 48.2% from $17.58M to $26.06M. Tissue-Based Revenue grew 12.7% to $81.49M.
Every figure comes from MDxHealth's annual financial filings, as reported. Each line keeps the name MDxHealth gives it, and years follow its fiscal calendar.
MDxHealth's revenue by products and services [axis] goes back to fiscal 2022, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.